https://www.sciencedaily.com/news/health_medicine/lymphoma/ Learn about lymphoma. Read the latest research on lymphoma symptoms, diagnosis, current lymphoma treatments. Find information on different lymphoma types including non-Hodgkin's lymphoma. en-us Thu, 12 Mar 2026 23:01:17 EDT Thu, 12 Mar 2026 23:01:17 EDT 60 https://www.sciencedaily.com/images/scidaily-logo-rss.png https://www.sciencedaily.com/news/health_medicine/lymphoma/ For more science news, visit ScienceDaily. https://www.sciencedaily.com/releases/2026/03/260303050624.htm Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more structured and treatable form—but it gets shut down by an overactive KRAS-driven pathway. When researchers blocked that pathway, GATA6 levels rebounded and cancer cells became more sensitive to chemo. The discovery could help turn some of the toughest pancreatic tumours into ones doctors can better control. Tue, 03 Mar 2026 11:33:04 EST https://www.sciencedaily.com/releases/2026/03/260303050624.htm https://www.sciencedaily.com/releases/2026/01/260114084129.htm Pancreatic cancer uses a sugar-coated disguise to evade the immune system, helping explain why it’s so hard to treat. Northwestern scientists discovered this hidden mechanism and created an antibody that strips away the tumor’s protective signal. In animal tests, immune cells sprang back into action and tumors grew much more slowly. The team is now refining the therapy for future human trials. Thu, 15 Jan 2026 02:10:05 EST https://www.sciencedaily.com/releases/2026/01/260114084129.htm https://www.sciencedaily.com/releases/2025/10/251019120527.htm Scientists have found that preserving lymph nodes during cancer surgery could dramatically improve how patients respond to immunotherapy. The research shows that lymph nodes are essential for training and sustaining cancer-fighting T cells. Removing them may unintentionally weaken the immune response, while keeping them intact could help unlock stronger, longer-lasting treatments. Mon, 20 Oct 2025 07:48:10 EDT https://www.sciencedaily.com/releases/2025/10/251019120527.htm https://www.sciencedaily.com/releases/2025/09/250902085154.htm Scientists have decoded the 3D structure of an ancient viral protein hidden in our DNA. The HERV-K Env protein, found on cancer and autoimmune cells, has a unique shape that could unlock new diagnostics and therapies. Wed, 03 Sep 2025 03:54:43 EDT https://www.sciencedaily.com/releases/2025/09/250902085154.htm https://www.sciencedaily.com/releases/2025/08/250803233100.htm Head and neck cancer, notoriously hard to treat, might have a new weakness—timing. Researchers discovered that syncing radiation and immunotherapy in just the right way can make tumors disappear in mice. By protecting the body’s immune system hubs, they’ve unlocked a potentially powerful method to fight aggressive cancers more effectively. Clinical trials are already underway, hinting at a new era in cancer treatment. Mon, 04 Aug 2025 00:35:24 EDT https://www.sciencedaily.com/releases/2025/08/250803233100.htm https://www.sciencedaily.com/releases/2025/06/250619090853.htm Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies. This one-shot strategy could revolutionize how we fight not just HIV, but many infectious diseases. It mimics the natural infection process and opens the door to broadly neutralizing antibody responses, a holy grail in vaccine design. And best of all, it's built on components already known to medicine. Thu, 19 Jun 2025 09:08:53 EDT https://www.sciencedaily.com/releases/2025/06/250619090853.htm https://www.sciencedaily.com/releases/2025/05/250515191230.htm A new gene editor may soon open the door to gene therapies for a wider array of diseases. Thu, 15 May 2025 19:12:30 EDT https://www.sciencedaily.com/releases/2025/05/250515191230.htm https://www.sciencedaily.com/releases/2025/05/250515132454.htm Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults. Research teams have now been able to demonstrate the function of epigenetic changes in the development of this cancer. Thu, 15 May 2025 13:24:54 EDT https://www.sciencedaily.com/releases/2025/05/250515132454.htm https://www.sciencedaily.com/releases/2025/05/250514180735.htm Some patients with lupus who possess specific antibodies are at a higher risk of thrombotic events such as a blood clot, stroke or heart attack, a new study shows. The finding might help clinicians determine which patients may need early treatment and clinical monitoring for thrombotic events. Wed, 14 May 2025 18:07:35 EDT https://www.sciencedaily.com/releases/2025/05/250514180735.htm https://www.sciencedaily.com/releases/2025/05/250507200803.htm A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. Wed, 07 May 2025 20:08:03 EDT https://www.sciencedaily.com/releases/2025/05/250507200803.htm https://www.sciencedaily.com/releases/2025/05/250501122441.htm Cancer scientists engineer a new type of antibody which could be used to boost the immune systems of patients fighting disease. Thu, 01 May 2025 12:24:41 EDT https://www.sciencedaily.com/releases/2025/05/250501122441.htm https://www.sciencedaily.com/releases/2025/05/250501121957.htm Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas. Thu, 01 May 2025 12:19:57 EDT https://www.sciencedaily.com/releases/2025/05/250501121957.htm https://www.sciencedaily.com/releases/2025/04/250429103008.htm A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in addition to a favorable safety profile and high in vivo persistence of CAR30+ cells. Tue, 29 Apr 2025 10:30:08 EDT https://www.sciencedaily.com/releases/2025/04/250429103008.htm https://www.sciencedaily.com/releases/2025/04/250428221209.htm Where you get your vaccine booster matters more than you think. Scientists in Sydney found that same-arm shots prime immune cells to respond faster, producing stronger antibodies against viruses like COVID-19 in the first week. This early edge could be crucial during outbreaks, giving people protection when it matters most. Mon, 28 Apr 2025 22:12:09 EDT https://www.sciencedaily.com/releases/2025/04/250428221209.htm https://www.sciencedaily.com/releases/2025/04/250422132004.htm Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of the immune system, which then go to work to clear an infection. A new study explores the factors that influence how effectively antibodies engage specific immune cells. Tue, 22 Apr 2025 13:20:04 EDT https://www.sciencedaily.com/releases/2025/04/250422132004.htm https://www.sciencedaily.com/releases/2025/04/250404122618.htm A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study. Fri, 04 Apr 2025 12:26:18 EDT https://www.sciencedaily.com/releases/2025/04/250404122618.htm https://www.sciencedaily.com/releases/2025/03/250325160113.htm Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many proteins group together in what are called protein complexes to carry out biological functions. The traditional method of generating antibodies by immunizing animals struggles to make antibodies related to these protein complexes. Scientists have now demonstrated that fusing protein complexes together adds stability during immunization and enables antibody generation. Tue, 25 Mar 2025 16:01:13 EDT https://www.sciencedaily.com/releases/2025/03/250325160113.htm https://www.sciencedaily.com/releases/2025/03/250318141359.htm A study has shown that lymph node transfer is a viable treatment for the swelling in the affected limb, a condition known as lymphedema, after breast cancer surgery. However, an effective drug to improve the outcomes of the transfer treatment continues to be sought. Tue, 18 Mar 2025 14:13:59 EDT https://www.sciencedaily.com/releases/2025/03/250318141359.htm https://www.sciencedaily.com/releases/2025/03/250303141854.htm Research has shown that tattoo ink does not just remain where it is injected. Particles from the ink can migrate to the lymph nodes, where they accumulate. Mon, 03 Mar 2025 14:18:54 EST https://www.sciencedaily.com/releases/2025/03/250303141854.htm https://www.sciencedaily.com/releases/2025/02/250213144435.htm When a tumour develops, it creates a structure around itself called the tumour stroma, within which blood and lymphatic vessels ensure nutritional and respiratory biological exchanges. Lymphangiogenesis, i.e. the development of lymphatic vessels, is generally associated with a poor prognosis, as it favours the spread of metastases to other organs. By studying the cells that make up the wall of lymphatic vessels, a team has made an unexpected discovery: an enzyme they express appears to play a key role in supporting immune cells, particularly when they are activated by anti-tumor treatments. These results could pave the way for improving the effectiveness of immunotherapies. Thu, 13 Feb 2025 14:44:35 EST https://www.sciencedaily.com/releases/2025/02/250213144435.htm https://www.sciencedaily.com/releases/2025/02/250212192458.htm Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose blood thinners. Wed, 12 Feb 2025 19:24:58 EST https://www.sciencedaily.com/releases/2025/02/250212192458.htm https://www.sciencedaily.com/releases/2025/02/250212151141.htm A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers. Wed, 12 Feb 2025 15:11:41 EST https://www.sciencedaily.com/releases/2025/02/250212151141.htm https://www.sciencedaily.com/releases/2025/01/250117161118.htm Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. But scientists have now discovered that for some HIV vaccines, something else happens: after a few immunizations the immune system begins to produce antibodies against immune complexes already bound to the viral protein alone. Fri, 17 Jan 2025 16:11:18 EST https://www.sciencedaily.com/releases/2025/01/250117161118.htm https://www.sciencedaily.com/releases/2025/01/250110122027.htm A look at cancer cells: Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their destruction. Their research presents the new type of molecular 3D visualization of antibody-cell interactions. The visualization of the molecular interaction between antibody and tumor cell opens up new avenues for improved immunotherapies against cancer. Fri, 10 Jan 2025 12:20:27 EST https://www.sciencedaily.com/releases/2025/01/250110122027.htm https://www.sciencedaily.com/releases/2024/12/241205184442.htm Researchers have found a new receptor for nerve growth factor that plays an important role in pain signaling, even though it does not signal on its own, according to a new study. The findings hold promise for finding new treatments for arthritis and other forms of inflammatory and cancer pain, without the side effects that led recent therapies to fail in clinical trials. Thu, 05 Dec 2024 18:44:42 EST https://www.sciencedaily.com/releases/2024/12/241205184442.htm https://www.sciencedaily.com/releases/2024/12/241205142530.htm An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. Thu, 05 Dec 2024 14:25:30 EST https://www.sciencedaily.com/releases/2024/12/241205142530.htm https://www.sciencedaily.com/releases/2024/11/241113123311.htm Why do some people develop severe flu symptoms? A study points the finger at an unsung portion of the antibodies our immune systems generate to fend off invading pathogens. Wed, 13 Nov 2024 12:33:11 EST https://www.sciencedaily.com/releases/2024/11/241113123311.htm https://www.sciencedaily.com/releases/2024/10/241031124220.htm With the goals of informing surgical management, improving long-term outcomes and lowering death rates of patients with testicular cancer, a study has found that the conventional, versatile open surgery approach to removal of the lymph nodes behind the intestines for patients whose testicular cancer has not advanced beyond the abdomen is the gold standard of care for men in this condition. Thu, 31 Oct 2024 12:42:20 EDT https://www.sciencedaily.com/releases/2024/10/241031124220.htm https://www.sciencedaily.com/releases/2024/10/241023130919.htm Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other conditions. The findings point to the possibility of developing such immunotherapies for heart failure in patients who have experienced a heart attack or other injury. Wed, 23 Oct 2024 13:09:19 EDT https://www.sciencedaily.com/releases/2024/10/241023130919.htm https://www.sciencedaily.com/releases/2024/10/241017113515.htm Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen. This is compared to 83% survival among patients who received standard care, after two years of follow-up. The study was designed to eliminate radiation, which can cause significant side effects and second cancers later in life. Researchers expect to see lower rates of breast cancer, infertility, heart disease, and other common radiation side effects years down the line for patients treated with nivolumab. Thu, 17 Oct 2024 11:35:15 EDT https://www.sciencedaily.com/releases/2024/10/241017113515.htm https://www.sciencedaily.com/releases/2024/09/240926132129.htm Research has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of drug-resistant infections. Using genetic and functional approaches, the researchers managed to unravel how these antibodies interact with antigens on the bacterial surface. They also found that some of these novel antibodies act synergistically to neutralize this pathogen. Thu, 26 Sep 2024 13:21:29 EDT https://www.sciencedaily.com/releases/2024/09/240926132129.htm https://www.sciencedaily.com/releases/2024/09/240920160801.htm Researchers have shown that they can generate a strong immune response against HIV with two doses of a vaccine given one week apart. Fri, 20 Sep 2024 16:08:01 EDT https://www.sciencedaily.com/releases/2024/09/240920160801.htm https://www.sciencedaily.com/releases/2024/09/240916115452.htm Monoclonal antibodies -- treatments developed by cloning a cell that makes an antibody -- could help provide an answer to the growing problem of antimicrobial resistance, say scientists. Mon, 16 Sep 2024 11:54:52 EDT https://www.sciencedaily.com/releases/2024/09/240916115452.htm https://www.sciencedaily.com/releases/2024/08/240820124435.htm Scientists have discovered why the flu vaccine can perform poorly. They found that a specific type of immune cell, called T follicular helper cells, indirectly controls the anti-influenza response. These helper cells often 'see' the wrong parts of the virus, likely leading to immunity that is less effective. Tue, 20 Aug 2024 12:44:35 EDT https://www.sciencedaily.com/releases/2024/08/240820124435.htm https://www.sciencedaily.com/releases/2024/08/240809135927.htm A 'loopy' discovery in bacteria is raising fundamental questions about the makeup of our own genome -- and revealing a potential wellspring of material for new genetic therapies. Fri, 09 Aug 2024 13:59:27 EDT https://www.sciencedaily.com/releases/2024/08/240809135927.htm https://www.sciencedaily.com/releases/2024/07/240722155148.htm Scientists have discovered a way to turn the body's B cells into tiny surveillance machines and antibody factories that can pump out specially designed antibodies to destroy cancer cells or HIV, two of medicine's most formidable foes. Mon, 22 Jul 2024 15:51:48 EDT https://www.sciencedaily.com/releases/2024/07/240722155148.htm https://www.sciencedaily.com/releases/2024/07/240722155017.htm The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study. Mon, 22 Jul 2024 15:50:17 EDT https://www.sciencedaily.com/releases/2024/07/240722155017.htm https://www.sciencedaily.com/releases/2024/06/240620152233.htm Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, including Hodgkin lymphoma. Checkpoint inhibitor therapies can be thought of as the molecular 'brake release' for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells in the body. Thu, 20 Jun 2024 15:22:33 EDT https://www.sciencedaily.com/releases/2024/06/240620152233.htm https://www.sciencedaily.com/releases/2024/06/240619143609.htm Recently, scientists found that some people who suffered from COVID-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signaling proteins. Now, researchers conducted an in-depth study on 123 Japanese COVID-19 patients to clarify just how common these auto-antibodies are among severe cases and how they affect the immune system. Their findings could shed light on the role of auto-antibodies in exacerbating COVID-19 severity. Wed, 19 Jun 2024 14:36:09 EDT https://www.sciencedaily.com/releases/2024/06/240619143609.htm https://www.sciencedaily.com/releases/2024/06/240612113309.htm CAR-T cell therapies are transforming the treatment of previously incurable blood cancers, but a large proportion of patients still responds only poorly or not at all to them, calling for new strategies to overcome this challenge. Now, a research team has developed a simple intervention in the form of a biodegradable scaffold material called 'T-cell enhancing scaffolds' (TES) that can be locally injected under the skin and used to restimulate CAR-T cells after their administration. This increased their therapeutic efficacy and significantly curbed tumor growth and prolonged animal survival in an aggressive mouse lymphoma model. Wed, 12 Jun 2024 11:33:09 EDT https://www.sciencedaily.com/releases/2024/06/240612113309.htm https://www.sciencedaily.com/releases/2024/06/240606152135.htm Scientists say they have developed an artificial lymph node with the potential to treat cancer, according to a new study in mice and human cells. Thu, 06 Jun 2024 15:21:35 EDT https://www.sciencedaily.com/releases/2024/06/240606152135.htm https://www.sciencedaily.com/releases/2024/05/240530132715.htm A new human monoclonal antibody moves a step closer to a universal antibody cocktail that works against all strains of SARS-CoV-2. Thu, 30 May 2024 13:27:15 EDT https://www.sciencedaily.com/releases/2024/05/240530132715.htm https://www.sciencedaily.com/releases/2024/05/240517164126.htm A study has found that repeat vaccination with updated versions of the COVID-19 vaccine promotes the development of antibodies that neutralize a wide range of variants of the virus that causes COVID-19, as well as related coronaviruses. Fri, 17 May 2024 16:41:26 EDT https://www.sciencedaily.com/releases/2024/05/240517164126.htm https://www.sciencedaily.com/releases/2024/05/240506131555.htm Researchers have found a way to enhance and extend LN expansion, and study how this phenomenon affects both the immune system and efficacy of vaccinations against tumors. While the oversized LNs maintained a normal tissue organization, they displayed altered mechanical features and hosted higher numbers of various immune cell types that commonly are involved in immune responses against pathogens and cancers. Importantly, 'jump-starting' lymph node expansion prior to administering a traditional vaccine against a melanoma-specific model antigen led to more effective and sustained anti-tumor responses in mice. Mon, 06 May 2024 13:15:55 EDT https://www.sciencedaily.com/releases/2024/05/240506131555.htm https://www.sciencedaily.com/releases/2024/04/240417131115.htm Investigators have discovered how brain cells responsible for working memory -- the type required to remember a phone number long enough to dial it -- coordinate intentional focus and short-term storage of information. Wed, 17 Apr 2024 13:11:15 EDT https://www.sciencedaily.com/releases/2024/04/240417131115.htm https://www.sciencedaily.com/releases/2024/04/240404190524.htm It is possible to leave most of the lymph nodes in the armpit, even if one or two of them have metastases larger than two millimeters. This is shown in a trial enrolling women from five countries. The results open up for gentler surgery for patients with breast cancer. Thu, 04 Apr 2024 19:05:24 EDT https://www.sciencedaily.com/releases/2024/04/240404190524.htm https://www.sciencedaily.com/releases/2024/04/240402140245.htm A novel treatment for leukemias and lymphomas that arise from immune system T cells was found to be effective at killing these cancers in mice bearing human T-cell tumors. Tue, 02 Apr 2024 14:02:45 EDT https://www.sciencedaily.com/releases/2024/04/240402140245.htm https://www.sciencedaily.com/releases/2024/03/240312133929.htm Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus. Tue, 12 Mar 2024 13:39:29 EDT https://www.sciencedaily.com/releases/2024/03/240312133929.htm https://www.sciencedaily.com/releases/2024/02/240214122524.htm Researchers have developed a new nanoparticle that can 'hitch a ride' on immune cells, or monocytes. Because of its tiny size, the particle can tag along directly into lymph nodes and help metastasis show up on MRIs where it would otherwise be too hard to detect. The process offers game-changing benefits for the early detection of cancer metastasis in the lymph nodes. While previously, metastasis could only be assessed by an increase in lymph node size; the new particles could lead to MRI contrast agents that can highlight metastatic cells in lymph nodes that may otherwise appear normal. Wed, 14 Feb 2024 12:25:24 EST https://www.sciencedaily.com/releases/2024/02/240214122524.htm https://www.sciencedaily.com/releases/2024/01/240126140550.htm Researchers have uncovered a distinctive network of lymphatic vessels at the back of the nose that plays a critical role in draining cerebrospinal fluid (CSF) from the brain. The study, sheds light on a previously unknown route for CSF outflow, potentially unlocking new avenues for understanding and treating neurodegenerative conditions. Fri, 26 Jan 2024 14:05:50 EST https://www.sciencedaily.com/releases/2024/01/240126140550.htm https://www.sciencedaily.com/releases/2024/01/240124172011.htm Antiretroviral therapy (ART) does an excellent job at suppressing HIV to undetectable levels in the blood. However, small amounts of latent virus hide throughout the body, and when treatment is stopped, it opens the door for the virus to rebound. Researchers identified which tissues SIV, the nonhuman primate version of HIV, reemerges from first, just seven days after ART is stopped. Wed, 24 Jan 2024 17:20:11 EST https://www.sciencedaily.com/releases/2024/01/240124172011.htm https://www.sciencedaily.com/releases/2024/01/240117183756.htm Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies -- a human broadly neutralizing antibody and two antibodies isolated from previously vaccinated monkeys -- target the fusion peptide, a site on an HIV surface protein that helps the virus fuse with and enter cells. Wed, 17 Jan 2024 18:37:56 EST https://www.sciencedaily.com/releases/2024/01/240117183756.htm https://www.sciencedaily.com/releases/2023/12/231211114516.htm Circulating tumor DNA predicts recurrence and splits disease into two subgroups of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity. Mon, 11 Dec 2023 11:45:16 EST https://www.sciencedaily.com/releases/2023/12/231211114516.htm https://www.sciencedaily.com/releases/2023/11/231116141025.htm Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to these treatments due to a loss of the antigen that's being targeted. Now, a new study has found that gene splicing occurring within these cells can cause significant changes in CD20 protein levels that render the therapies ineffective. Thu, 16 Nov 2023 14:10:25 EST https://www.sciencedaily.com/releases/2023/11/231116141025.htm https://www.sciencedaily.com/releases/2023/11/231115113347.htm New research shows that a cocktail of drugs already approved to treat high blood pressure quickly reduces brain swelling and improves outcomes in animal models of brain injury.  Wed, 15 Nov 2023 11:33:47 EST https://www.sciencedaily.com/releases/2023/11/231115113347.htm https://www.sciencedaily.com/releases/2023/11/231109121538.htm Allergic responses to common foods such as dairy and peanuts can increase the risk for heart disease and cardiovascular death as much or more than smoking, new research suggests. And these dangerous allergic responses can strike both people with food allergies and those with no obvious allergy symptoms. Thu, 09 Nov 2023 12:15:38 EST https://www.sciencedaily.com/releases/2023/11/231109121538.htm https://www.sciencedaily.com/releases/2023/11/231106134855.htm Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg. The research also describes how the youth obesity epidemic is expected to affect the cancer situation over the next 30 years. Mon, 06 Nov 2023 13:48:55 EST https://www.sciencedaily.com/releases/2023/11/231106134855.htm https://www.sciencedaily.com/releases/2023/11/231103141405.htm Researchers have pioneered a novel treatment for the most common autoimmune encephalitis. By reprogramming white blood cells to target and eliminate disease-causing cells, the approach offers a new level of precision and efficiency. The technique has proven successful in laboratory studies, clinical trials in humans are already being planned. Fri, 03 Nov 2023 14:14:05 EDT https://www.sciencedaily.com/releases/2023/11/231103141405.htm https://www.sciencedaily.com/releases/2023/11/231102135135.htm Antibiotic-resistant bacteria pose a major challenge to healthcare systems worldwide. Due to numerous resistance mechanisms, infections with the pathogen Pseudomonas aeruginosa are particularly feared. Researchers have now discovered antibodies that could lead to a highly potent treatment option of acute and chronic infections with P. aeruginosa. Thu, 02 Nov 2023 13:51:35 EDT https://www.sciencedaily.com/releases/2023/11/231102135135.htm https://www.sciencedaily.com/releases/2023/09/230913134305.htm During a bout of influenza, B cells interact with other immune cells and then take different paths to defend the body. One path is the B cells that differentiate into lung-resident memory B cells, or lung-BRMs, that are critical for pulmonary immunity. These long-lived, non-circulating lung-BRMs migrate to the lungs from draining lymph nodes and reside there permanently as the first layer of defense that can quickly react to produce antibodies in a future infection. Wed, 13 Sep 2023 13:43:05 EDT https://www.sciencedaily.com/releases/2023/09/230913134305.htm